(Q36825547)

16 August 2017

title

[3H]MDL 100,907: a novel selective 5-HT2A receptor ligand (English)

1 reference

16 August 2017

M P Johnson

1

1 reference

16 August 2017

B W Siegel

series ordinal

2

1 reference

16 August 2017

A A Carr

series ordinal

3

1 reference

16 August 2017

publication date

1 July 1996

1 reference

Naunyn-Schmiedeberg's Archives of Pharmacology

16 August 2017

published in

1 reference

16 August 2017

volume

354

1 reference

16 August 2017

issue

2

1 reference

16 August 2017

page(s)

205-209

1 reference

https://scigraph.springernature.com/pub.10.1007/bf00178722

16 August 2017

exact match

0 references

cites work

Contribution of serotonin neurotoxins to understanding psychiatric disorders: the role of 5-HT2 receptors in schizophrenia and antipsychotic activity.

1 reference

12 December 2020

Activities of novel aryloxyalkylimidazolines on rat 5-HT2A and 5-HT2C receptors

1 reference

12 December 2020

Electrophysiological, biochemical and behavioral evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic function

1 reference

12 December 2020

Characterization and regional distribution of serotonin S2-receptors in human brain.

1 reference

12 December 2020

Receptor binding profile of R 41 468, A novel antagonist at 5-HT2 receptors

1 reference

12 December 2020

Different subcellular localization of muscarinic and serotonin (S2) receptors in human, dog, and rat brain.

1 reference

12 December 2020

Role and localization of serotonin-5HT2 receptors

1 reference

12 December 2020

Blockade of striatal 5-hydroxytryptamine2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine

1 reference

12 December 2020

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

1 reference

12 December 2020

[3H]Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role.

1 reference

12 December 2020

Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile

1 reference

12 December 2020

Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors.

1 reference

12 December 2020

Species differences in the pharmacology of the 5-hydroxytryptamine2 receptor: structurally specific differentiation by ergolines and tryptamines

1 reference

12 December 2020

Reversal of amphetamine-induced behaviours by MDL 100,907, a selective 5-HT2A antagonist.

1 reference

12 December 2020

[3H]ketanserin labels 5-HT2 receptors and alpha 1-adrenoceptors in human and pig brain membranes

1 reference

12 December 2020

Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies.

1 reference

12 December 2020

Naphthosultam derivatives: a new class of potent and selective 5-HT2 antagonists

1 reference

12 December 2020

Characterization of two [3H]ketanserin recognition sites in rat striatum.

1 reference

12 December 2020

5-HT2 receptors exert a state-dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine

1 reference

12 December 2020

Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors

1 reference

12 December 2020

Identification of nonserotonergic [3H]ketanserin binding sites associated with nerve terminals in rat brain and with platelets; relation with release of biogenic amine metabolites induced by ketanserin- and tetrabenazine-like drugs.

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00178722

1 reference

16 August 2017

1 reference